There are currently 14 active clinical trials seeking participants for Plaque Psoriasis research studies. The states with the highest number of trials for Plaque Psoriasis participants are California, Ontario, Texas and Florida.
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
NCT04036188
Recruiting
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Wright State Physicians, Fairborn, Ohio
Conditions: Plaque Psoriasis, Vitamin D3
Register for Updates
A Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738
Recruiting
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psorias... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama +103 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
NCT06586112
Recruiting
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psorias... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Alliance Dermatology, Phoenix, Arizona +145 locations
Conditions: Plaque Psoriasis
Register for Updates
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Alliance Dermatology, Pheonix, Arizona +31 locations
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Total Dermatology, Birmingham, Alabama +274 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219
Recruiting
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/20/2025
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +50 locations
Conditions: Plaque Psoriasis
Register for Updates
Role of Insulin Action in Psoriasis Pathogenesis
NCT06242847
Recruiting
The goal of this study is to collect more information from people with plaque psoriasis and to determine if insulin plays a role in the pathogenesis of psoriasis. The main question it aims to answer is if insulin action is preserved or even enhanced in psoriatic lesions despite insulin resistance elsewhere. Participants with plaque psoriasis will have punch biopsies taken of lesional and non-lesional skin after an overnight fast and then during an oral glucose tolerance test. Biopsy specimens wi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +29 locations
Conditions: Plaque Psoriasis
Register for Updates
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
Recruiting
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
12/05/2024
Locations: Dermavant Clinical Site, Rogers, Arkansas +18 locations
Conditions: Plaque Psoriasis
Register for Updates
Topical SGX302 for Mild-to-Moderate Psoriasis
NCT05442190
Recruiting
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Therapeutics Clinical Research, San Diego, California
Conditions: Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Register for Updates
Bimekizumab in Plaque Psoriasis
NCT06336343
Recruiting
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleuk... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey +1 locations
Conditions: Plaque Psoriasis
Register for Updates
Guselkumab Immunogenetics
NCT04645355
Recruiting
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: UCSF Psoriasis and Skin Treatment Center, San Francisco, California
Conditions: Psoriasis Guttate, Plaque Psoriasis
Register for Updates